For help on how to get the results you want, see our search tips.
1738 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Orphan designations Remove Orphan designations filter
Opinions on maximum residue limits Remove Opinions on maximum residue limits filter
Orphan designation status
Positive Remove Positive filter
-
List item
Orphan designation: Tadekinig alfa for: Treatment of haemophagocytic lymphohistiocytosis (updated)
Date of first decision: 14/10/2016, Positive, Last updated: 19/02/2021 -
List item
Orphan designation: Recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB linked to the human IgG1 Fc domain (luspatercept) for: Treatment of beta thalassaemia intermedia and major (updated)
Date of first decision: 29/07/2014, Positive, Last updated: 18/02/2021 -
List item
Orphan designation: Recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB linked to the human IgG1 Fc domain (luspatercept) for: Treatment of myelodysplastic syndromes (updated)
Date of first decision: 22/08/2014, Positive, Last updated: 18/02/2021 -
List item
Orphan designation: Luspatercept for: Treatment of myelofibrosis (updated)
Date of first decision: 28/02/2020, Positive, Last updated: 18/02/2021 -
List item
Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) for: Treatment of spinal muscular atrophy (updated)
Date of first decision: 14/12/2018, Positive, Last updated: 09/02/2021 -
List item
Orphan designation: Autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor (lisocabtagene maraleucel) for: Treatment of diffuse large B-cell lymphoma (updated)
Date of first decision: 17/07/2017, Positive, Last updated: 09/02/2021 -
List item
Orphan designation: Autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor (lisocabtagene maraleucel) for: Treatment of follicular lymphoma (updated)
Date of first decision: 25/05/2018, Positive, Last updated: 09/02/2021 -
List item
Orphan designation: Lisocabtagene maraleucel for: Treatment of primary mediastinal large B-cell lymphoma (updated)
Date of first decision: 19/11/2018, Positive, Last updated: 09/02/2021 -
List item
Orphan designation: Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-hydroxy-,15,15'-diester with N-acetyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-alpha-aspartyl-L-tryptophylglycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-L-threonyl-2-[2-(2-aminoethoxy)ethoxy]acetyl-N6-carboxy-L-lysinamide cyclic (2.fwdarw.12)-(disulfide); where two identical synthetic peptide domains are covalently linked at the ends of the polyethylene glycol chain (pegcetacoplan) for: Treatment of C3 glomerulopathy (updated)
Date of first decision: 21/08/2019, Positive, Last updated: 03/02/2021 -
List item
Orphan designation: 2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione for: Treatment of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (updated)
Date of first decision: 12/12/2017, Positive, Last updated: 03/02/2021 -
List item
Orphan designation: ciclosporin for: Treatment of moderate and severe closed traumatic brain injury (updated)
Date of first decision: 01/10/2010, Positive, Last updated: 03/02/2021 -
List item
Orphan designation: 2-Hydroxyoleic acid for: Treatment of glioma (updated)
Date of first decision: 27/10/2011, Positive, Last updated: 03/02/2021 -
List item
Orphan designation: Oxalobacter formigenes strain HC-1 for: Treatment of primary hyperoxaluria (updated)
Date of first decision: 17/02/2006, Positive, Last updated: 02/02/2021 -
List item
Orphan designation: Oxalobacter formigenes strain HC-1 for: Treatment of short bowel syndrome (updated)
Date of first decision: 15/10/2014, Positive, Last updated: 02/02/2021 -
List item
Orphan designation: Somapacitan for: Treatment of growth hormone deficiency (updated)
Date of first decision: 24/08/2018, Positive, Last updated: 01/02/2021 -
List item
Orphan designation: pemigatinib for: Treatment of myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK (updated)
Date of first decision: 17/10/2019, Positive, Last updated: 01/02/2021 -
List item
Orphan designation: Clofazimine for: Treatment of nontuberculous mycobacterial lung disease (updated)
Date of first decision: 21/08/2019, Positive, Last updated: 28/01/2021 -
List item
Orphan designation: Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti CD19 CD28/CD3-zeta chimeric antigen receptor and cultured (KTE-X19) for: Treatment of mantle cell lymphoma
Date of first decision: 13/11/2019, Positive, Last updated: 25/01/2021 -
List item
Orphan designation: recombinant human interleukin-3 truncated diphtheria toxin fusion protein for: Treatment of blastic plasmacytoid dendritic cell neoplasm
Date of first decision: 11/11/2015, Positive, Last updated: 25/01/2021 -
List item
Orphan designation: Oxytocin for: Treatment of Prader-Willi syndrome
Date of first decision: 29/07/2014, Positive, Last updated: 25/01/2021 -
List item
Orphan designation: dimethyl fumarate for: Adjunctive treatment in haematopoietic cell transplantation
Date of first decision: 21/03/2018, Positive, Last updated: 15/01/2021 -
List item
Orphan designation: Fenfluramine hydrochloride for: Treatment of Dravet syndrome
Date of first decision: 18/12/2013, Positive, Last updated: 08/01/2021 -
List item
Orphan designation: Autologous CD34+ cells transfected with lentiviral vector containing the human arylsulfatase A cDNA for: treatment of metachromatic leukodystrophy
Date of first decision: 13/04/2007, Positive, Last updated: 22/12/2020 -
List item
Orphan designation: Miransertib for: Treatment of Proteus syndrome
Date of first decision: 21/03/2018, Positive, Last updated: 22/12/2020 -
List item
Orphan designation: Obeticholic acid for: Treatment of primary sclerosing cholangitis
Date of first decision: 16/03/2014, Positive, Last updated: 22/12/2020